Skip to content
MARKETS / BALCAO / VASO
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Vaso Corp. VASO

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$89.1M
▲ 2.7% YoY
$1.6M
▲ 65.0% YoY
In brief

What this company does

Vaso Corporation principally operates in three distinct business segments in the healthcare equipment and information technology industries. Vaso Corporation's IT segment, operating through wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services, with healthcare IT services divested in November 2025. Vaso Corporation's professional sales service segment, operating through wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, focuses on the sale of healthcare capital equipment for GE HealthCare Technologies, Inc. into the health provider middle market. Vaso Corporation's equipment segment focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business. Vaso Corporation was incorporated in Delaware in July 1987. As of December 31, 2025, Vaso Corporation employed 282 full-time persons across its headquarters and VasoMedical facility in Plainview, New York, VasoHealthcare, NetWolves operations, and China operations. Vaso Corporation is headquartered in Plainview, Long Island, New York, pursuant to a lease that expires in September 2028.

Written from the business description in VASO CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 89.1M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 89.1 · Net income 1.6
40M80M201020122014201620182020202220242025
Compound annual growth
+4.0%
+5.0%
+4.6%
+12.0%
−48.2%
+34.4%
−8.5%
−45.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.0% a year over five years — but profit grew faster: net income at +34.4%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
2 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -3.2% · Net 1.8%
5%10%-10%-20%201020122014201620182020202220242025
ROE
FY2025 · ROE 5.5%
20%40%60%-5%201020122014201620182020202220242025

Each USD of equity produced 5 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF 13.8
5M10M-2M-4M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2015 · Dividends — · Net buybacks 0.0
0.8M1.6M2012201320142015

Total assetsUSD 88.3M
EquityUSD 29.4M
CashUSD 35.0M
Gross debtUSD 286,000.00
Net debtUSD -34.8M
Current ratio1.59×

The company holds more cash than debt.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.10.10.10.10.10.10.10.10.00.00.00.00.0
Operating income $B−0.00.00.00.00.00.00.0−0.0−0.00.00.00.0−0.0−0.00.0−0.0
EBITDA $B−0.00.00.00.00.00.00.0−0.0−0.00.00.00.0−0.0−0.0·−0.0
Income tax $B−0.00.00.0−0.00.00.00.0−0.00.00.0−0.00.0−0.00.0·0.0
Net income $B0.00.00.00.00.00.0−0.0−0.0−0.00.00.00.0−0.0−0.00.0−0.0
Free cash flow $B···0.00.00.0−0.0−0.0−0.00.00.00.0−0.00.0·0.0
EPS, diluted $0.010.010.030.06·0.000.00−0.02−0.030.010.020.01−0.01−0.020.02−0.04
Dividend / sh $················
Payout %················
ROE %5.53.519.668.175.57.6−8.9·········
Shares out B0.180.180.180.180.180.170.170.170.170.160.160.160.160.160.15·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 75 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 20 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image